Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients
Although interferon (IFN) free antiviral therapy is expected to improve the treatment response for chronic hepatitis C, the effect on liver function and liver fibrosis is unknown. In this study, we analyzed the long term follow up of liver function parameters and liver fibrosis markers in genotype 1b hepatitis C virus (HCV) infected patients treated with daclatasvir and asunaprevir.
Hepatology research the official journal of the Japan Society of Hepatology